본 바이올로직스BBLG 주가

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-upBURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The up

Bone Biologics Announces Validated Shelf Life Extension Of Its rhNELL-1 Protein Product To 29 Months

The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the

BBLG In Good Shape as Critical Tests Underway

By Brad Sorensen, CFA NASDAQ: BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively

Bone Biologics Q1 EPS $(0.43) Beats $(0.54) Estimate

Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 77.6 percent increase over losses of $(1.92) per share from the

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

[424B5] 증자 가격 공시 — 424B5

[10-K] 연 실적 — 10-K

[4] 내부자 거래 — 4

[4] 내부자 거래 — 4